Sign In
17 Apr 2015 07:00
Biofrontera starts with robust growth into the new year
· Preliminary Q1 numbers indicate revenue increased by 59% to over EUR 1.0m
· German revenues up 44%
· Euro 247k from EU sales outside Germany
Leverkusen, 17 April 2015 - Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical company focusing on skin cancer, has recorded robust revenue growth at the beginning of the new fiscal year. According to preliminary numbers for the first quarter, total revenues were more than Euro 1.0m with Euro 247k generated outside Germany, mainly in Scandinavia and Austria. In Germany revenues increased by 44% compared to the first quarter of the previous year and amounted to Euro 783k.
Professor Hermann Lübbert, Chairman of the Executive Board, commented: "We are very pleased with business development so far in the current year. We had repeatedly emphasized that we would expect much larger revenues in 2015 and the first quarter has fully confirmed our expectations. Growth in Germany is even higher than anticipated. Although we do not extrapolate this growth and maintain our guidance for the full year, this development provides us some tail wind for the coming months."
Besides the expansion of the operational business Biofrontera's focus for this fiscal year remains on two strategic goals: approval of our leading product Ameluz® for the treatment of actinic keratosis in the USA as well as the expansion of the approved indication to basal cell carcinoma in Europe. Both goals should be met by 2016.
Final numbers will be announced with the Company's quarterly report on 29 May 2015.
Ends
Enquiries, please contact:
Biofrontera AG Prof. Hermann Lübbert, Chief Executive Officer Thomas Schaffer, Chief Financial Officer | +49 (0) 214 87 63 2 0 press@biofrontera.com www.biofrontera.com |
IR Germany: Brainwell Asset Solutions Jürgen Benker | +49 (0) 152 08931514 |
Nomad and Broker: Shore Capital Bidhi Bhoma / Toby Gibbs | +44(0) 20 7408 4090 |
IR UK: Seton Services Toni Vallen | +44(0) 20 7603 6797 |
Financial PR: Gable Communications John Bick | +44(0) 20 7193 7463 +44 (0)7872 061007 |
Background:
The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.
The company also markets the Belixos® dermatological range of cosmetics. Belixos® products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos® cream, gel and scalp tonic are available through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
www.biofrontera.com
This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.
Follow the stocks
